You are viewing the site in preview mode
Skip to main content
|
Variables
|
Original cohort
|
P-value
|
Matched cohort
|
P-value
|
|---|
|
MIPD (N = 20)
|
OPD (N = 66)
|
MIPD (N = 17)
|
OPD(N = 34)
|
|---|
|
Age (years)
|
74.5 ± 6.77
|
72.48 ± 5.35
|
0.234
|
73.76 ± 5.68
|
73.70 ± 6.82
|
0.974
|
|
Male (Male)
|
14 (70.0%)
|
40 (60.6%)
|
0.313
|
13 (76.5%)
|
25 (73.5%)
|
0.553
|
|
Malignancy (n, %)
|
19 (95%)
|
59 (84.9%)
|
0.402
|
16 (94.1%)
|
32 (94.1%)
|
> 0.999
|
|
CCI (n, %)
| | |
0.211
| | |
0.558
|
|
0
|
6 (30.0%)
|
28 (42.4%)
| |
6 (35.3%)
|
12 (35.3%)
| |
|
1
|
6 (30.0%)
|
22 (33.3%)
| |
6 (35.3%)
|
12 (35.3%)
| |
|
2
|
7 (35.0%)
|
12 (18.2%)
| |
4 (23.5%)
|
8 (23.5%)
| |
|
3
|
0 (0%)
|
3 (4.5%)
| |
0 (0%)
|
2 (5.9%)
| |
|
4
|
0 (0%)
|
1 (1.5%)
| |
0 (0%)
|
0 (0%)
| |
|
5
|
1 (5.0%)
|
0 (0%)
| |
1 (5.9%)
|
0 (0%)
| |
|
ASA (n, %)
| | |
0.388
| | |
0.463
|
|
I
|
0 (0%)
|
0 (0%)
| |
0 (0%)
|
0 (0%)
| |
|
II
|
5 (25.0%)
|
21 (31.8%)
| |
4 (23.5%)
|
10 (29.4%)
| |
|
III
|
15 (75.0%)
|
45 (68.2%)
| |
13 (76.5%)
|
24 (70.6%)
| |
|
Tumor type (n, %)
| | |
0.402
| | |
0.583
|
|
Benign
|
1 (5.0%)
|
6 (9.1%)
| |
1 (3.8%)
|
2 (5.9%)
| |
|
Ampullary cancer
|
9 (45.0%)
|
16 (24.2%)
| |
7 (41.2%)
|
10 (29.4%)
| |
|
CBD cancer
|
4 (20.0%)
|
11 (16.7%)
| |
3 (17.6%)
|
8 (23.5%)
| |
|
PDAC
|
5 (25.0%)
|
26 (39.4%)
| |
5 (29.4%)
|
12 (35.3%)
| |
|
IPMN
|
0 (0%)
|
3 (4.5%)
| |
0 (0%)
|
2 (5.9%)
| |
|
PNET
|
0 (0%)
|
3 (4.5%)
| |
0 (0%)
|
0 (0%)
| |
|
Duodenal cancer
|
1 (5.0%)
|
1 (1.5%)
| |
1 (5.9%)
|
0 (0%)
| |
|
ECOG (n, %)
| | |
0.008
| | |
0.042
|
|
0
|
13 (65.0%)
|
61 (92.4%)
| |
12 (70.6%)
|
32 (94.1%)
| |
|
1
|
5 (25.0%)
|
4 (6.1%)
| |
3 (17.6%)
|
2 (5.9%)
| |
|
2
|
2 (10%)
|
1 (1.5%)
| |
2 (11.8%)
|
0 (0%)
| |
|
Tumor size (cm ± SD)
|
2.98 ± 1.93
|
3.26 ± 1.49
|
0.562
|
2.8. ± 2.0
|
2.92 ± 1.25
|
0.844
|
|
Lymph node harvest (number ± SD)
|
15.35 ± 8.26
|
19.42 ± 9.88
|
0.075
|
16.94 ± 8.56
|
17.44 ± 7.77
|
0.840
|
|
Pre-op bile drain (n, %)
|
8 (66.7%)
|
39 (59.1%)
|
0.696
|
10 (58.8%)
|
21(61.8%)
|
0.537
|
|
Abdominal surgery history (n, %)
|
4 (20.0%)
|
13 (19.7%)
|
0.601
|
3 (17.6%)
|
8 (23.5%)
|
0.462
|
- Italic indicate statistic significance
- PSM propensity score matching, MIPD minimal invasive pancreatoduodenectomy, OPD open pancreatoduodenectomy, CCI Charlson comorbidity index, ASA score American Society of Anesthesiologists classification score, ECOG Eastern Cooperative Oncology Group
